Safety of long-term proactive management with fixed-dose combination calcipotriene 0.005% and betamethasone dipropionate 0.064% foam in patients with psoriasis vulgaris: Results of a phase III, multicenter, randomized, 52-week, vehicle-controlled trial

被引：0
|
作者：
Lebwohl, Mark [1 ]
Lacour, Jean Philippe [2 ]
Liljedahl, Monika [3 ]
Lynde, Charles [3 ]
Morch, Marie [3 ]
Snel-Prento, Anja [3 ]
Thaci, Diamant [4 ]
Warren, Richard B. [5 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Univ Hosp Nice, Dept Dermatol, Nice, France
[3] Leo Pharma, Ballerup, Denmark
[4] Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany
[5] Univ Manchester, Manchester, Lancs, England
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2020年 / 83卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
12797
引用
收藏
页码：AB1 / AB1
页数：1
相关论文
共 48 条
  • [21] Safety and efficacy of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase II, open-label trial
    Seyger, M.
    Abramovits, W.
    Liljedahl, M.
    Hoejen, M. N.
    Teng, J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (09) : 2026 - 2034
  • [22] Safety and Efficacy of Clindamycin Phosphate 1.2% Benzoyl Peroxide 3% Fixed-Dose Combination Gel for the Treatment of Acne Vulgaris: A Phase 3, Multicenter, Randomized, Double-Blind, Active- and Vehicle-Controlled Study
    Eichenfield, Lawrence F.
    Saenz, Alessandra B. Alio
    JOURNAL OF DRUGS IN DERMATOLOGY, 2011, 10 (12) : 1382 - 1396
  • [23] Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis
    Papp, K.
    Bachelez, H.
    Costanzo, A.
    Foley, P.
    Gooderham, M.
    Kaur, P.
    Philipp, S.
    Spelman, L.
    Zhang, N.
    Strober, B.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (06) : 1562 - 1574
  • [24] LONG-TERM 52-WEEK RESULTS OF PALACE 3, A PHASE 3, RANDOMIZED, CONTROLLED TRIAL OF APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS AND CURRENT SKIN INVOLVEMENT
    Edwards, Christopher J.
    Blanco, Francisco J.
    Crowley, Jeffrey
    Hu, ChiaChi
    Stevens, Randall M.
    Birbara, Charles A.
    RHEUMATOLOGY, 2014, 53 : 138 - 139
  • [25] Long-Term (52-Week) Results Of a Phase 3, Randomized, Controlled Trial Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis and Current Skin Involvement (PALACE 3)
    Edwards, Christopher J.
    Blanco, Francisco J.
    Crowley, Jeffrey
    Hu, ChiaChi
    Stevens, Randall M.
    Birbara, Charles A.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S132 - S132
  • [26] Long-term 52-week results of PALACE 3, a phase 3, randomized controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement
    Edwards, C.
    Blanco, F.
    Crowley, J.
    Hu, C. C.
    Stevens, R.
    Birbara, C.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2014, 43 : 67 - 68
  • [27] Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial
    Edwards, Christopher J.
    Aelion, Jacob A.
    Adebajo, Adewale O.
    Kivitz, Alan
    Bird, Paul
    Hu, ChiaChi
    Stevens, Randall M.
    Wells, Alvin
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S694 - S695
  • [28] APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (52-WEEK) IMPROVEMENTS IN BASDAI IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED RESULTS FROM 3 PHASE III, RANDOMIZED, CONTROLLED TRIALS
    Mease, P.
    Marzo-Ortega, H.
    Poder, A.
    Van den Bosch, F.
    Wollenhaupt, J.
    Lespessailles, E.
    McIlraith, M.
    Teng, L.
    Hall, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 341 - 341
  • [29] Long-Term Safety and Efficacy of Certolizumab Pegol in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis: 5-Year Results from a 52-Week Randomized Controlled Trial and Open-Label Extension Study
    Keystone, Edward
    Landewe, Robert
    van Vollenhoven, Ronald
    Combe, Bernard
    Strand, Vibeke
    Mease, Phillip
    Shaughnessy, Laura
    VanLunen, Brenda
    van der Heijde, Desiree
    JOURNAL OF RHEUMATOLOGY, 2014, 41 (07) : 1455 - 1456
  • [30] LONG-TERM SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS: 5-YEAR RESULTS FROM A 52-WEEK RANDOMIZED CONTROLLED TRIAL AND OPEN-LABEL EXTENSION STUDY
    Keystone, Edward
    Landewe, Robert
    van Vollenhoven, Ronald
    Combe, Bernard
    Strand, Vibeke
    Mease, Philip J.
    Shaughnessy, Laura
    vanlunen, Brenda
    van der Heijde, Desiree
    RHEUMATOLOGY, 2014, 53 : 96 - 96
12345